Skip to main content
 

Caribou Biosciences Co-Founder Dr. Jennifer Doudna Named to TIME Magazine's TIME 100 - TIME's Annual List of the 100 Most Influential People in the World

April 16, 2015

Caribou Biosciences, a developer of CRISPR-Cas9 technologies for precision cell engineering, today announced that co-founder Jennifer Doudna, Ph.D., has been named to TIME magazine's TIME 100 - TIME's annual list of the 100 most influential people in the world. Dr. Doudna is being recognized for harnessing CRISPR-Cas systems to establish a transformative gene-editing technology platform.

"We are excited and proud to see Jennifer's scientific accomplishments recognized through her inclusion in this year's TIME 100," said Rachel Haurwitz, Ph.D., Chief Executive Officer and co-founder of Caribou Biosciences. "Jennifer's discoveries and inventions in the CRISPR-Cas9 genome editing field are poised to revolutionize biology and medicine."

Dr. Doudna’s work on CRISPR-Cas systems has previously been recognized by the award of a Breakthrough Prize in Life Sciences, the Paul Janssen Award for Biomedical Research and a Lurie Prize in Biomedical Sciences.

The TIME 100 list, now in its twelfth year, recognizes the activism, innovation and achievement of the world’s most influential individuals. The full list and related tributes appear in the April 27 issue of TIME, available on newsstands and tablets on Friday, April 17, and now at time.com/time100.

About Caribou Biosciences

Caribou Biosciences is a developer of technology-based solutions for cellular engineering and analysis based on CRISPR-Cas9 biology. Caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

Media Contact

Greg Kelley
Vice President
Feinstein Kean Healthcare
(404) 836-2302
gregory.kelley@fkhealth.com